| Item Type | Name |
|
Concept
|
Antineoplastic Agents
|
|
Concept
|
Antineoplastic Agents, Alkylating
|
|
Concept
|
Antineoplastic Agents, Hormonal
|
|
Concept
|
Antineoplastic Agents, Phytogenic
|
|
Academic Article
|
A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer.
|
|
Academic Article
|
A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
|
|
Academic Article
|
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review.
|
|
Academic Article
|
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
|
|
Academic Article
|
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
|
|
Academic Article
|
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
|
|
Academic Article
|
Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.
|
|
Academic Article
|
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers.
|
|
Academic Article
|
A Phase II study of oxaliplatin in urothelial cancer.
|
|
Academic Article
|
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
|
|
Academic Article
|
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
|
|
Academic Article
|
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
|
|
Academic Article
|
Irinogenetics: what is the right star?
|
|
Academic Article
|
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium.
|
|
Academic Article
|
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
|
|
Academic Article
|
Aspiration in chemoradiated patients with head and neck cancer.
|
|
Academic Article
|
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.
|
|
Academic Article
|
Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers.
|
|
Academic Article
|
A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.
|
|
Academic Article
|
A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma.
|
|
Academic Article
|
Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer.
|
|
Academic Article
|
Head and neck cancer in 2010: Maximizing survival and minimizing toxicity.
|
|
Academic Article
|
Phase II study of sunitinib malate in head and neck squamous cell carcinoma.
|
|
Academic Article
|
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).
|
|
Academic Article
|
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
|
|
Academic Article
|
Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy.
|
|
Academic Article
|
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
|
|
Academic Article
|
The cancer and leukemia group B respiratory committee.
|
|
Academic Article
|
A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer.
|
|
Academic Article
|
Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
The role of EGFR inhibition in the treatment of non-small cell lung cancer.
|
|
Academic Article
|
Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer.
|
|
Academic Article
|
Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers.
|
|
Academic Article
|
Trends and perspectives in multimodality therapy of locoregionally advanced non-small cell lung cancer.
|
|
Academic Article
|
Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer.
|
|
Academic Article
|
The chemoradiation paradigm in head and neck cancer.
|
|
Academic Article
|
The concurrent chemoradiation paradigm--general principles.
|
|
Academic Article
|
Expanding role of the medical oncologist in the management of head and neck cancer.
|
|
Academic Article
|
Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
|
|
Academic Article
|
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
|
|
Academic Article
|
Current treatments and promising investigations in a multidisciplinary setting.
|
|
Academic Article
|
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.
|
|
Academic Article
|
Introduction: head and neck cancer.
|
|
Academic Article
|
Combining radiotherapy with systemic therapies.
|
|
Academic Article
|
Induction chemotherapy: to use or not to use? That is the question.
|
|
Academic Article
|
Recommended guidelines for the treatment of cancer treatment-induced diarrhea.
|
|
Academic Article
|
Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress.
|
|
Academic Article
|
Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
|
|
Academic Article
|
Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?
|
|
Academic Article
|
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
|
|
Academic Article
|
Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
|
|
Academic Article
|
A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).
|
|
Academic Article
|
New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer.
|
|
Academic Article
|
Seeking improved outcome in the curative treatment of non-small-cell lung cancer.
|
|
Academic Article
|
Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer.
|
|
Academic Article
|
Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting.
|
|
Academic Article
|
Cetuximab in cancers of the lung and head & neck.
|
|
Academic Article
|
Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235.
|
|
Academic Article
|
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
|
|
Academic Article
|
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].
|
|
Academic Article
|
Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.
|
|
Academic Article
|
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).
|
|
Academic Article
|
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
|
|
Academic Article
|
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
|
|
Academic Article
|
ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
|
|
Academic Article
|
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
|
|
Academic Article
|
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
|
|
Academic Article
|
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
|
|
Academic Article
|
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
|
|
Academic Article
|
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
|
|
Academic Article
|
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
|
|
Academic Article
|
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
|
|
Academic Article
|
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
|
|
Academic Article
|
Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains?
|
|
Academic Article
|
A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer.
|
|
Academic Article
|
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
|
|
Academic Article
|
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
|
|
Academic Article
|
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
|
|
Concept
|
Antineoplastic Agents, Immunological
|
|
Academic Article
|
Unification of Efforts to Improve Global Access to Cancer Therapeutics: Report From the 2022/2023 Access to Essential Cancer Medicines Stakeholder Summit.
|